System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Tobias Maurer is an expert in Urology at University Medical Center Hamburg-Eppendorf (Germany). As of October 2026, ScienceLeadR ranks Tobias Maurer in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Tobias Maurer has authored 505 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 5 of them ongoing. SLR score: 1,721 (community average: 125). How the SLR is computed.

LeadR Profile

Tobias Maurer University Medical Center Hamburg-Eppendorf Germany
1 721 ScienceLeadR Reputation 1721

Unlock

Register Login
Network Map

Urology

Subspecialties: Oncology - Nuclear Medicine - Histology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1991 - 2026
Source: PubMed

University Medical Center Hamburg-Eppendorf

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 505

Citations

Citations: 16 256 1st author: 81 Last author: 97 Unique author: 10

Main journals

J Urol 40
EUR UROL SUPPL 39
Eur Urol 39
J Nucl Med 37
Eur J Nucl Med Mol Imaging 24

Best Journals

J Clin Oncol 4
Eur Heart J 1
JAMA 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors.
PMID 42926195 — cells, dna repair, androgens, receptors, androgen, neoplasms, prostate, organoids, proteomics, prostatic neoplasms, therapeutics, medical oncology, tissues, immunoblotting		J Exp Clin Cancer Res20260
Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics.
PMID 42900232 — urology, neoplasms, prostate, neoplasm metastasis, prostatic neoplasms, castration, therapeutics		World J Urol20260
Factors associated with long-distance travel among patients undergoing radical prostatectomy at a German high-volume tertiary prostate cancer centre.
PMID 42776261 — travel, urology, neoplasms, prostate, insurance, prostatic neoplasms, prostatectomy		World J Urol20260
Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk.
PMID 42706231 — urinary bladder, urinary bladder neoplasms, biological science disciplines, neoplasms, multiple chronic conditions, smoking		Nat Commun20261
Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.
PMID 42637826 — tomography, pathology, prostate, positron emission tomography computed tomography, prostatic neoplasms, prostatectomy		Prostate Cancer Prostatic Dis20261

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 5
Phase 3 2
Phase 1/Phase 2 1
Phase 2 1

By status:

Recruiting 4
Active not recruiting 3
Completed 2

By type:

Interventional 9

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 2
multicentricup10 3

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with ADT in men with elevated blood levels of a specific protein called PSA which is a marker for high risk of prostate cancer recurrence
2022-501343-33-00 — blood, androgens, neoplasms, prostate, prostatic neoplasms, therapeutics, men		Phase 3Active not recruiting2023
Safety and diagnostic performance of uPAR PET imaging in localised untreated prostate cancer
2023-507111-35-00 — safety, positron-emission tomography, neoplasms, classification, prostate, prostatic neoplasms		Phase 1/Phase 2Recruiting2024
Navigation Outcomes and Quality of life in Prostate Cancer Patients Undergoing PSMA targeted Surgery
NCT07129551 — quality of life, lymph nodes, neoplasms, adenocarcinoma, prostate, neoplasm metastasis, lymph, prostatic neoplasms, prostatectomy, dissection		N/ARecruiting2026
Safety and Diagnostic Performance of uPAR PET Imaging in Localised Untreated Prostate Cancer
NCT06474806 — injections, chelating agents, safety, pharmaceutical preparations, positron-emission tomography, neoplasms, classification, prostate, biopsy, prostatic neoplasms		Phase 2Recruiting2024
Prostate Imaging Using MRI Contrast Enhancement
NCT04571840 — multiparametric magnetic resonance imaging, neoplasms, multiple chronic conditions, prostate, biopsy, prostatic neoplasms, diagnosis		N/AActive not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS